Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

0.8790 +0.0420 (+5.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Focused Ultrasound May Offer Easier Way to Treat Brain Tumors Effectively
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials
Via Investor Brand Network
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers OpGen (NASDAQ:OPGN) shares rose 20.6% to $0.52 during Monday's after-market session. This security traded at a volume of 927.4K shares come close, making up 324.6% of its average volume over... 
Via Benzinga
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright 24th Annual Global Investment Conference
Via Investor Brand Network
Study Suggests That Test of Memory May Signal Brain Tumor Presence
Via Investor Brand Network
Symptoms of Brain Tumors To Watch For
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin
Via Investor Brand Network
Accessibility Issues Prevent Individuals in Rural Areas from Undergoing Lifesaving Tumor Treatment
Via Investor Brand Network
Topics Death
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), Moving the Needle in GBM and Brain Cancer Research
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product
Via Investor Brand Network
Study Looks into Why Deadly Brain Tumors Continue to Grow After Treatment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Continues Priority to Advance Clinical Development Program for Berubicin
Via Investor Brand Network
Targeted Cancer Vaccines Show Promise in Halting Tumor Progression
Via Investor Brand Network
Topics Death
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2022 Financial Results, Corporate Update
Via Investor Brand Network
Researchers Want to Manage Cancer By Keeping Malignant Cells Restricted in Place
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Positioning Berubicin Clinical Development Program for Success
Via Investor Brand Network
Study Finds That Ketogenic Diet May Help Patients with Brain Cancer
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advances Drug Candidate to Fight Aggressive Brain Cancer Amid Difficult Era for Market
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment
Via Investor Brand Network
Researchers Develop Blood Test to Improve Tumor Diagnosis, Monitoring
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Urges Shareholders to Vote in Favor of Proxy Proposals for Upcoming Annual Meeting
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Expanding Patient Eligibility in Potentially Pivotal Berubicin Trial
Via Investor Brand Network
Preclinical Study Uncovers Potential Key to Treating Deadly Brain Tumors
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expands Patient Eligibility for Brain Cancer Drug Trial, Receives Approval from U.S. FDA for Protocol Amendment
Via Investor Brand Network
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
AI May Help Improve Brain Cancer Diagnosis
Via Investor Brand Network
Topics Artificial Intelligence
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures FDA Approval for Protocol Amendment to Ongoing Potentially Pivotal Berubicin Trial
Via Investor Brand Network
44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering. 
Via Benzinga
Study Suggests Healthcare Workers Don’t Know Enough About Childhood Brain Tumors
Via Investor Brand Network
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.